You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Microsatellite stable colorectal

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial (KN046, regorafenib)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Aug 2, 2023

Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma

Not yet recruiting
  • Advanced Colorectal Adenocarcinoma
  • +5 more
  • Balstilimab
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma Trial in Shanghai (Vitamin E, Fruquintinib, Tislelizumab)

Not yet recruiting
  • Colorectal Cancer
  • Microsatellite Stable Colorectal Carcinoma
  • Vitamin E
  • +2 more
  • Shanghai, Shanghai, China
    270 Dongan Road, Fudan University Shanghai Cancer Center
Mar 5, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • all trans Retinoic Acid
  • +2 more
  • (no location specified)
Aug 11, 2023

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

Terminated
  • Metastatic Colon Adenocarcinoma
  • +27 more
  • San Francisco, California
  • +1 more
Jan 5, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)

Recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • Experimental drug
  • Control Rx
  • Hefei, Anhui, China
  • +11 more
Mar 13, 2023

CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at

Withdrawn
  • CCR5
  • +3 more
  • 700mg leronlimab weekly dose
  • +3 more
  • (no location specified)
Feb 15, 2023

Microsatellite Stable Metastatic Colorectal Cancer Trial in Tucson, Aurora, New Brunswick (ALX148, Cetuximab, Pembrolizumab)

Recruiting
  • Microsatellite Stable Metastatic Colorectal Cancer
  • Tucson, Arizona
  • +2 more
Jul 28, 2022

Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis Trial in Shanghai (a combination therapy)

Not yet recruiting
  • Advanced Rectal Cancer
  • +3 more
  • a combination therapy including tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 9, 2022

Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite

Recruiting
  • Advanced Microsatellite Stable Colorectal Carcinoma
  • +5 more
  • Atlanta, Georgia
  • +2 more
Oct 29, 2021

Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

Recruiting
  • Colorectal Liver Metastases
  • Radiation: High- and Low-dose radiotherapy
  • PD-1 Inhibitors
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Sep 13, 2023

Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma Trial in

Active, not recruiting
  • Colorectal Adenocarcinoma
  • +7 more
  • Atlanta, Georgia
  • +2 more
May 6, 2022

Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)

Recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Feb 26, 2022

Microsatellite Stable Metastatic Colorectal Cancer Trial in Shanghai (Regorafenib, Toripalimab, High/low-dose radiotherapy)

Recruiting
  • Microsatellite Stable Metastatic Colorectal Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 19, 2023

Microsatellite Stable Colorectal Cancer Trial in United States (grapiprant, grapiprant and pembrolizumab)

Active, not recruiting
  • Microsatellite Stable Colorectal Cancer
  • Phoenix, Arizona
  • +3 more
Apr 21, 2022

Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma Trial in Baltimore (Nivolumab, Relatlimab)

Recruiting
  • Microsatellite Stable (MSS) Colorectal Adenocarcinomas
  • Colorectal Adenocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer Trial in Milano

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • +3 more
  • Milano, MI, Italy
    Istituto Nazionale dei Tumori
Jan 24, 2022

Metastatic Colorectal Cancer, MSS Trial in Heidelberg (Pembrolizumab, Maraviroc)

Completed
Has Results
  • Metastatic Colorectal Cancer
  • MSS
  • Heidelberg, Germany
    National Center for Tumor Diseases, University Hospital Heidelbe
May 17, 2022

Colorectal Cancer Trial (Irinotecan, Temozolomide)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 1, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma Trial in Rochester

Recruiting
  • Metastatic Colon Adenocarcinoma
  • +10 more
  • Colorectal Cancer Peptide Vaccine PolyPEPI1018
  • Trifluridine and Tipiracil Hydrochloride
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 10, 2022

Colorectal Cancer Trial in United Kingdom (Nivolumab)

Active, not recruiting
  • Colorectal Cancer
  • Belfast, United Kingdom
  • +13 more
Sep 14, 2021

Metastatic Microsatellite Stable Colorectal Cancer Trial in Boston (Nivolumab, Ipilimumab, Radiation Therapy)

Recruiting
  • Metastatic Microsatellite Stable Colorectal Cancer
  • Boston, Massachusetts
  • +2 more
Apr 27, 2021

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting
  • Anal Squamous Cell Carcinoma
  • +7 more
  • Regorafenib in combination with Tislelizumab
  • (no location specified)
Oct 12, 2022